MinichMacGregor Wealth Management LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 319,306 shares of the company’s stock, valued at approximately $32,098,000. iShares U.S. Pharmaceuticals ETF accounts for approximately 5.4% of MinichMacGregor Wealth Management LLC’s portfolio, making the stock its biggest holding. MinichMacGregor Wealth Management LLC owned approximately 2.06% of iShares U.S. Pharmaceuticals ETF at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Heritage Oak Wealth Advisors LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the first quarter valued at about $530,000. Tidal Investments LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth about $3,716,000. Schuylkill Financial LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the second quarter valued at approximately $992,000. Bank of America Corp DE boosted its position in shares of iShares U.S. Pharmaceuticals ETF by 2.8% in the 1st quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock worth $39,579,000 after purchasing an additional 12,565 shares in the last quarter. Finally, Compass Financial Management LLC purchased a new position in iShares U.S. Pharmaceuticals ETF during the second quarter valued at $565,000.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of IHE traded up $2.38 during trading hours on Wednesday, hitting $99.74. The company had a trading volume of 357,889 shares, compared to its average volume of 165,532. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of 17.75 and a beta of 0.47. The firm has a fifty day moving average price of $102.61 and a 200-day moving average price of $96.34. iShares U.S. Pharmaceuticals ETF has a 52-week low of $73.42 and a 52-week high of $108.66.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Further Reading
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
- How a Hurricane Could Help Some Refineries—and Hurt Others
- Intel Bets on Cheaper AI as Foundry Losses Mount
- Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could Deepen
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
